Nexthera Capital’s AstraZeneca AZN Stock Holding History

Nexthera Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-96,640	Closed	-$7.65M	–	28
2018 Q3	$7.65M	Sell	96,640 -163,500	-63%	-$12.4M	1.47%	22
2018 Q2	$18.3M	Buy	260,140 +18,140	+7%	+$1.31M	2.83%	8
2018 Q1	$16.9M	Buy	+242,000	New	+$16.8M	2.79%	9
2017 Q1	–	Sell	-150,000	Closed	-$8.73M	–	39
2016 Q4	$8.2M	Buy	+150,000	New	+$8.52M	4.8%	6

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nexthera Capital's AZN Position: Q4 2018 in Review

Nexthera Capital sold out of AstraZeneca (AZN) in Q4 2018, closing a stake of 96,640 shares — an estimated $7.65M sold.

Nexthera Capital first reported a position in AZN in Q4 2016 and held it in 4 quarters. The position peaked at $18.3M in Q2 2018. 556 funds tracked by Wall St. Rank hold AZN as of Q4 2018.

Nexthera Capital reported no remaining AstraZeneca position as of Q4 2018 after selling out during the quarter.
Nexthera Capital sold 96,640 AstraZeneca shares in Q4 2018, an estimated $7.65M.
Nexthera Capital first reported a position in AstraZeneca in Q4 2016 and held it in 4 quarters.
Nexthera Capital's AstraZeneca position peaked at $18.3M in Q2 2018.
556 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.